Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
Crossref DOI link: https://doi.org/10.1186/s13048-016-0239-6
Published Online: 2016-05-14
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fransson, Åsa
Glaessgen, Daria
Alfredsson, Jessica
Wiman, Klas G.
Bajalica-Lagercrantz, Svetlana
Mohell, Nina
Funding for this research was provided by:
the Swedish Cancer Society (130260, 140616)